The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients

• Status: Terminated
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Comparative analysis of the severity of Hand-Foot-Syndrome (HFS) of palms treated with brimonidine tartrate gel or with standard care Urea 10% containing lotion in cancer patients receiving antineoplastic therapy to show a preventive effect of cutaneous brimonidine treatment on severity of HFS symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Heinrich-Heine University, Duesseldorf
• Treatments: Brimonidine Tartrate

Criteria

Inclusion Criteria:

• Cancer patients with solid tumors under antineoplastic therapy with capecitabine or pegylated liposomal doxorubicin.

• Patients with a life expectancy of at least 12 weeks.

• History of HFS (grades 2 to 3) in the course of the therapy

• Patients who are 18-65 years old.

• Regression of HFS to grade 1 or lower with a symmetrical grading on both hands (grade 0 or grade 1) prior to the next cycle of chemotherapy.

• not legally incapacitated

• Written informed consent from the trial subject has been obtained.

• Current treatment with capecitabine or pegylated liposomal doxorubicin

Exclusion Criteria:

• Persons with any kind of dependency on the investigator or employed by the sponsor or investigator.

• Persons held in an institution by legal or official order.

• Participation in other interventional trials

• Drug & substance abuse

• Use of central nervous depressants (e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics)

• Patients taking alpha adrenergic agonists as medication.

• Pregnant women and nursing mothers

• Failure to use highly-effective contraceptive methods

The following contraceptive methods with a Pearl Index lower than 1% are regarded as highly effective:

• Oral hormonal contraception ('pill')

• Vaginal hormonal contraception (NuvaRing®)

• Contraceptive plaster

• Long-acting injectable contraceptives

• Implants that release progesterone (Implanon®)

• Tubal ligation (female sterilization)

• Intrauterine devices that release hormones (hormone spiral)

• Double barrier methods: This means that the following are not regarded as safe: condom plus spermicide, simple barrier methods (vaginal pessaries, condom, female condoms), copper spirals, the rhythm method, basal temperature method, and the withdrawal method (coitus interruptus).

• History of inflammatory dermatosis of hands or feet (e.g. hand eczema)

• Smoking

• Severe or unstable or uncontrolled cardiovascular disease

• Depression

• cerebral or coronary insufficiency

• Raynaud's phenomenon

• orthostatic hypotension

• thrombangiitis obliterans

• Scleroderma

• Sjögren's syndrome

• renal or hepatic impairment

• Known allergic sensitization against any of the substances applied in the study

• Patients receiving monoamine oxidase (MAO) inhibitor therapy (for example selegiline or moclobemide) and patients on tricyclic (such as imipramine) or tetracyclic (such as maprotiline, mianserin or mirtazapin) antidepressants which affect noradrenergic transmission.

• Patients receiving topical corticoids on hands or feet within 1 week prior to baseline measurement and during the entire study treatment period of up to six weeks.